In honor of Women’s History Month, our Women’s Philanthropy division wants you to know about Federation’s efforts to improve the lives of Jewish Women everywhere. Our Women’s Impact Initiative Grants are supporting two organizations that help Jewish women understand their […]
Sharsharet and Yodeah — two nonprofits whose work is centered around breast cancer screenings, support, education and awareness of the heightened risk for hereditary genetic mutations faced by Jewish women and men — are making sure Breast Cancer Awareness month […]
For Haleigh Youtie, her life halted 6-months ago when she lost her mother, Eileen after an 8-year battle with breast cancer. Over her 8 year-long fight Eileen made it her mission to get all Ashkenazi Jews tested for a Breast […]
Yodeah announces the creation of the Chazak Award to recognize amazing people who have inspired our mission and worked with Yodeah to save generations of Jewish families through education and testing for Jewish hereditary cancers. The Hebrew word Chazak means […]
THE MOST RELEVANT GENES FOR COMMON HEREDITARY CANCERS
* CDK4: analysis is limited to chr12:g.58145429-58145431 (codon 24). EPCAM: analysis is limited to deletions that minimally encompass the 3′ end of the gene including exons 8 and/or 9. GREM1: analysis is limited to duplications that overlap the upstream regulatory region. MITF: analysis is limited to chr3:g.70014091 (including c.952G>A). MUTYH: single heterozygous pathogenic variants, likely pathogenic variants, and variants of uncertain significance are not reported. PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). POLD1: analysis is limited to chr19:g.50909713 (including c.1433G>A). POLE: analysis is limited to chr12:g.133250250 (including c.1270C>G).